Can you tell me about guidelines for treating asthama latest
Reading File
Finding Sources
Searching PubMed
"asthma" AND "guidelines" AND "management"
Searching the Web
GINA 2025 asthma guidelines latest update treatment recommendations
Finding Sources
Reading Web Page
GINA 2025 asthma guidelines treatment steps recommendations
Finding Sources
Searching the Web
GINA 2025 biologic therapy severe asthma step 5 dupilumab tezepelumab recommendations
I now have comprehensive information to provide a thorough answer about the latest GINA 2025 asthma guidelines. Here is the full, structured response:
Asthma Treatment Guidelines - GINA 2025
The Global Initiative for Asthma (GINA) 2025 strategy report (published May 2025, updated November 2025) is the current gold standard for asthma management. Here is a complete overview:
1. Diagnosis
- Confirm variable airflow limitation with spirometry or PEF (pre/post bronchodilator)
- In adults/adolescents: FeNO > 50 ppb or blood eosinophils above the lab reference range support a diagnosis of asthma when spirometry is unavailable or negative
- In children: FeNO > 35 ppb is the threshold
- Treat immediately if acutely unwell, and test simultaneously - do not delay therapy waiting for test results
- Lower FeNO or eosinophils do NOT rule out asthma
2. Two Treatment Tracks (Steps 1-5)
GINA 2025 maintains the dual-track approach introduced in 2020-21:
Track 1 (Preferred) - ICS-Formoterol as Reliever
The preferred approach because it reduces severe exacerbations, oral corticosteroid courses, and urgent healthcare visits. Uses a single inhaler across Steps 1-4.
| Step | Treatment |
|---|---|
| Step 1-2 | As-needed low-dose ICS-formoterol only (AIR - Anti-Inflammatory Reliever) |
| Step 3 | Low-dose maintenance ICS-formoterol + as-needed ICS-formoterol (MART - Maintenance And Reliever Therapy) |
| Step 4 | Medium-dose maintenance ICS-formoterol + as-needed ICS-formoterol (MART) |
| Step 5 | Add LAMA (e.g., tiotropium) + refer for phenotype assessment + consider biologics |
Example inhalers: Symbicort 100/6 (Steps 1-3), Symbicort 200/6 (Step 4)
Track 2 - ICS + SABA Reliever
| Step | Treatment |
|---|---|
| Step 1 | As-needed SABA + low-dose ICS with each SABA dose |
| Step 2 | Daily low-dose ICS maintenance + SABA reliever |
| Step 3 | Low-dose ICS-LABA maintenance + SABA reliever |
| Step 4 | Medium-dose ICS-LABA + SABA reliever |
| Step 5 | Add LAMA + refer for phenotype/biologic assessment |
SABA overuse warning: GINA 2025 strongly emphasizes the risks of SABA-only therapy and overuse. Track 1 is preferred precisely because it eliminates the "SABA-only" default.
3. MART (Maintenance And Reliever Therapy)
- MART uses ICS-formoterol for both regular maintenance and as-needed relief
- Reduces severe exacerbations vs. other maintenance regimens including ICS-LABA + SABA
- Only ICS-formoterol combinations can be used for MART - other ICS-LABA combinations (e.g., salmeterol-fluticasone) cannot
4. Step 5 - Severe Asthma Management
When symptoms remain uncontrolled despite Step 4 treatment:
- Reassess the diagnosis, comorbidities, inhaler technique, and adherence first
- Refer for specialist assessment and inflammatory phenotyping (blood eosinophils, FeNO, sputum eosinophils)
- Consider add-on:
- LAMA (e.g., tiotropium/Spiriva Respimat)
- Low-dose azithromycin (for frequent exacerbations)
- High-dose ICS-formoterol trial
Biologic Therapies (phenotype-guided)
| Phenotype | Preferred Biologic |
|---|---|
| Allergic (high IgE) | Omalizumab (anti-IgE) |
| Type-2 high with eosinophilia | Mepolizumab, benralizumab, reslizumab (anti-IL-5/IL-5R) |
| Mixed Type-2 / high FeNO + eosinophils | Dupilumab (anti-IL-4Rα) |
| Type-2 low (no eosinophilia, low IgE) | Tezepelumab (anti-TSLP, works upstream) |
GINA 2025 introduced a new framework distinguishing clinical remission vs. complete/pathophysiological remission - relevant especially to biologic therapy assessment. Long-term safety data should be tracked up to 5 years.
5. Key 2025 Updates
- Personalized asthma management (PAM): GINA 2025 elevated this to a formal, structured strategy using the Assess-Adjust-Review cycle covering diagnosis, symptom control, comorbidities, inhaler technique, adherence, and patient goals
- Age-specific guidance: New targeted recommendations for children under 5 years old
- Biomarker integration: Blood eosinophils and FeNO now formally used to identify Type-2 inflammation and tailor treatment
- Severe asthma decision tree (Boxes 8-2 to 8-5): Reorganized and simplified; confirmation of severe asthma diagnosis moved to Stage 5 after specialist assessment
- Reassessment of low T2 biomarkers: Prompt to re-evaluate previously low eosinophils/FeNO if clinical context changes
- Climate change: New guidance acknowledging environmental/climate factors in asthma
6. Acute Exacerbation Management
- Mild-to-moderate: Increase as-needed ICS-formoterol (MART) or add SABA to maintenance ICS
- Moderate: Short course of oral corticosteroids (OCS), 40-50 mg prednisolone/day for 5-7 days
- Severe/life-threatening: Hospital admission, IV magnesium sulfate, controlled oxygen, nebulized SABA + ipratropium, systemic corticosteroids; consider ICU if refractory
7. Non-Pharmacological Measures
- Allergen and irritant avoidance (dust mites, mold, pets, smoking, occupational exposures)
- Weight loss in obese patients
- Exercise encouraged with pre-treatment if needed
- Annual influenza vaccination
- Breathing exercises as adjunct therapy
- Shared decision-making and written asthma action plans
Recent Evidence Note
A major 2025 meta-analysis (ORACLE2, Lancet Respir Med, PMID: 40215991) identified key inflammatory and clinical risk factors for asthma attacks across 22 RCTs, further supporting the biomarker-guided approach in GINA 2025.
The full GINA 2025 report and summary guide are available at ginasthma.org.
Key take-home message from GINA 2025: Track 1 with ICS-formoterol as the anti-inflammatory reliever is the preferred strategy at all steps for adults and adolescents. SABAs as the sole reliever are no longer recommended. Biologic therapy selection at Step 5 should always be guided by inflammatory phenotype (T2 vs. non-T2), not empirically chosen.
This is a shared conversation. Sign in to Orris to start your own chat.